Clinical trial
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
NCT06483100 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
- Lead sponsor
- Washington University School of Medicine
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 20, 2024
- Completion date
- June 30, 2032
- Enrollment
- 65 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.